12th Annual Pulmonary Hypertension Symposium 2021
Pulmonary Hypertension (PH )is an often overlooked cause of right ventricular dysfunction causing Coronary Artery Failure (CHF). There is tremendous need for improved identification of PH and timely referral to appropriate treatment centers. Because of specialized methods, patients and providers face obstacles to therapy access. Patient outcomes are significantly improved when close follow up and frequent monitoring are implemented into the plan of care. Current research is being done to investigate the systemic effects of this vascular process, reinforcing the importance of the multidisciplinary approach to treatment of Pulmonary Arterial Hypertension (PAH).
This conference is being held virtually.
This course is intended for all physicians, internists, family medicine physicians, cardiologists, pulmonologists, rheumatologists, pharmacists, APNs, nurses, fellows, residents, and Allied Health Professionals.
At the end of this session, learners should be able to:
- Explore the pathophysiology of PAH and associated conditions
- Discuss known pathways of treatment and identify research targets
- Integrate diagnostic evaluation, newly available medical therapies, and strategies for implementation of early treatment for PAH patients
- Explore different imaging and diagnostic modalities used to assess severity of PH and right ventricular status
- Evaluate screening methods and opportunities for early referrals to PH specialists in patients with pulmonary embolism
- Discuss treatment options for CTEPH.
- Identify process for CTEPH identification and referral to expert surgical center to ensure best patient outcomes.
- Recognize available options and methodology for early aggressive combination therapy in PAH.
- Distinguish between the differing ideologies of when to treat in combined pre and postcapillary PH
- Explain how the COVID-19 pandemic has impacted the identification and care of patients with PH.
Muyyaldeen Dia, MD; Advocate Aurora Health
Valerie LaRoy, APN; Advocate Aurora Health
Nicole Victor, NP; Advocate Aurora Health
Moutaz Sunbuli, MD; Advocate Aurora Health
Nichole Panos, Administrative Assistant, Advocate Aurora Health
Patroklos Pappas, MD, Medical Director, Advocate Heart Institute at Christ Medical Center
William R. Auger, MD, CTEPH Program Director Emeritus, University of California, San Diego
Christopher Sciamanna, DO, Advanced Heart Failure, Mechanical Circulatory Support, Transplant Cardiology & Pulmonary Hypertension Clinical Assistant Professor of Medicine, University of Illinois at Chicago
Nicole Victor, MSN, FNP-BC and Molly Sokolowski, FNP-BC Pulmonary Hypertension Program, Advocate Heart Institute at Advocate Christ Medical Center
Moutaz Sunbuli, MD, Pulmonary Hypertension Clinic, Advocate Heart Institute at Advocate Christ Medical Center
Muhyaldeen Dia, MD, FACC, FCCP, FASE, Medical Director, Pulmonary Hypertension Program, Advocate Heart Institute at Christ Medical Center and Associate Program Director, University of Illinois at Chicago/Advocate Christ Medical Center
Susan Serratore RN BSN SANE-A, SANE-P, Coordinator Medical Staff Professional Development, Advocate South Suburban Hospital
The following faculty speakers and/or planning committee members have disclosed the following:
Name of Ineligible Companies
Nature of Relationship
Muhyaldeen Dia, MD
United Therapeutics and Bayer
|Valerie LaRoy, APN||Janssen and United Therapeutics|
United Therapeutics and Bayer
|William R. Auger, MD||Bayer, Actelion, and Cereno Scientific|
The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. Conflict of interest have been identified and mitigated prior to the activity.
Advocate Aurora Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Advocate Aurora Health designates this live activity for a maximum of 3.25 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Part II
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with the ABIM through the ACCME Program and Activity Reporting System (PARS).
- 3.25 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 3.25 AttendanceAttendance Credit
- 3.25 Approved AMA PRA Category 1 Credit™
- 3.25 ABIM MOC Part IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Click “Take Course” to register for this program.
A Microsoft Teams link to join the virtual 12th Annual Pulmonary Hypertension Symposium will be sent to you via email before the start of the course.
If you have any questions or need assistance please contact: Nichole Panos at (708) 684-5860 or Nichole.Panos@aah.org